Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Wenhui Lou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0710-4403; OpenAlex author ID A5102904590. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
62
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: none · 2022: 6 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 22

  1. Deciphering molecular crosstalk mechanisms between skeletal muscle atrophy and KRAS-mutant pancreatic cancer: a literature review. Last author DOI 10.21037/hbsn-24-282↗
  2. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. First author DOI 10.3892/ol.2024.14293↗
  3. Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection ma… Last author DOI 10.3389/fonc.2023.1109068↗
  4. Tumor-associated N1 and N2 neutrophils predict prognosis in patients with resected pancreatic ductal adenocarcinoma: A preliminary study. Co-author DOI 10.1002/mco2.183↗
  5. Deep insight into lymph node metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2022.06.027↗
  6. A metabolism-relevant signature as a predictor for prognosis and therapeutic response in pancreatic cancer. Co-author DOI 10.1177/15353702211049220↗
  7. Commentary on "Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… Last author DOI 10.1245/s10434-022-12148-1↗
  8. Application of dynamic contrast enhanced ultrasound in distinguishing focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.3233/ch-221390↗
  9. Prognostic Effect of Age in Resected Pancreatic Cancer Patients: A Propensity Score Matching Analysis. Last author DOI 10.3389/fonc.2022.789351↗
  10. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Last author DOI 10.1016/j.canlet.2019.06.013↗
  11. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.21037/atm.2019.10.91↗
  12. Independent effect of postoperative neutrophil-to-lymphocyte ratio on the survival of pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy an… Co-author DOI 10.7150/jca.35856↗
  13. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. Co-author DOI 10.1186/s12967-018-1673-6↗
  14. A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. Co-author DOI 10.1038/bjc.2017.365↗
  15. SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells. Co-author DOI 10.1177/1010428317695913↗
  16. Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection. Co-author DOI 10.7150/jca.20917↗
  17. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/md.0000000000004527↗
  18. Long-term survival following total pancreatectomy and superior mesenteric-portal vein resection for pancreatic ductal adenocarcinoma: A case report. Co-author DOI 10.3892/ol.2014.2628↗
  19. LIN28B suppresses microRNA let-7b expression to promote CD44+/LIN28B+ human pancreatic cancer stem cell proliferation and invasion. Co-author PMID 26609473↗
  20. iTRAQ-based quantitative proteomics reveals myoferlin as a novel prognostic predictor in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.jprot.2013.06.032↗
  21. Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma. First author DOI 10.3892/ol.2013.1261↗
  22. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Co-author DOI 10.1007/s10238-011-0159-0↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenchuan Wu · 13 shared papers, 2012–2024 · strength 1.53
  2. Dansong Wang · 13 shared papers, 2012–2025 · strength 1.28
  3. Ning Pu · 9 shared papers, 2017–2022 · strength 1.11
  4. Hanlin Yin · 7 shared papers, 2018–2022 · strength 0.96
  5. Dayong Jin · 10 shared papers, 2012–2024 · strength 0.81
  6. Tiantao Kuang · 9 shared papers, 2012–2024 · strength 0.77
  7. Yaolin Xu · 4 shared papers, 2022–2025 · strength 0.70
  8. Xuefeng Xu · 7 shared papers, 2015–2024 · strength 0.68
  9. Qiangda Chen · 4 shared papers, 2019–2022 · strength 0.61
  10. Jun Yu · 3 shared papers, 2019–2022 · strength 0.42
  11. Weisheng Yu · 2 shared papers, 2022–2025 · strength 0.41
  12. Yefei Rong · 5 shared papers, 2012–2024 · strength 0.38
  13. Shanshan Gao · 4 shared papers, 2017–2022 · strength 0.38
  14. Yuan Ji Ma · 3 shared papers, 2013–2024 · strength 0.36
  15. Xi Guo · 2 shared papers, 2023–2024 · strength 0.32
  16. Lili Wu · 2 shared papers, 2023–2024 · strength 0.32
  17. Haokang Feng · 1 shared paper, 2025 · strength 0.22
  18. Xu Han · 1 shared paper, 2025 · strength 0.22
  19. Huaxiang Xu · 1 shared paper, 2025 · strength 0.22
  20. Yuquan Guo · 1 shared paper, 2025 · strength 0.22
  21. Yue Fan · 1 shared paper, 2023 · strength 0.17
  22. Yuhong Zhou · 1 shared paper, 2023 · strength 0.17
  23. Dan Zuo · 1 shared paper, 2022 · strength 0.16
  24. Qi Zhang · 1 shared paper, 2022 · strength 0.16
  25. Yijie Qiu · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.